Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.33 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17954272 | 0.92 | AKT1 (0.33) | FBP1P2RY2P2RY4P2RY6 | |
| SCHEMBL20799470 | 0.87 | FBP1 (0.33) | FBP1 | |
| SCHEMBL17954223 | 0.86 | FBP1 (0.35) | FBP1P2RY2P2RY4P2RY6 | |
| SCHEMBL27049120 | 0.83 | FBP1 (0.40) | FBP1P2RY2P2RY4P2RY6AMDHD2 | |
| SCHEMBL24833622 | 0.83 | P2RY2 (0.43) | FBP1P2RY2P2RY4P2RY6 | |
| SCHEMBL20215996 | 0.80 | AKT1 (0.30) | — | |
| SCHEMBL20673146 | 0.80 | FBP1 (0.43) | FBP1P2RY2P2RY4P2RY6 | |
| SCHEMBL29631772 | 0.80 | FBP1 (0.43) | FBP1P2RY2P2RY4P2RY6 | |
| SCHEMBL26549773 | 0.80 | FBP1 (0.33) | FBP1 | |
| SCHEMBL17954224 | 0.79 | FBP1 (0.31) | FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008570-B2 | 3′ end caps for RNAi agents for use in RNA interference | NOVARTIS AG (CH) | 2021-05-18 | — | — | US | disclosed |
| US-10519446-B2 | Organic compounds to treat hepatitis B virus | NOVARTIS AG (CH) | 2019-12-31 | — | — | US | disclosed |
| US-10227588-B2 | 3′end caps for RNAi agents for use in RNA interference | NOVARTIS AG (CH) | 2019-03-12 | — | — | US | disclosed |
| US-9988627-B2 | Formats for organic compounds for use in RNA interference | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| US-9988627-B2 | Formats for organic compounds for use in RNA interference | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160244756-A1 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-08-25 | — | — | US | disclosed |
| US-20160244756-A1 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-08-25 | — | — | US | disclosed |
| US-20160215288-A1 | ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160215288-A1 | ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227588-B2 | 3′end caps for RNAi agents for use in RNA interference | RNGTT, NSUN2, NSUN3 | FBP1 2002/4885P2RY2 4503/4885P2RY4 4586/4885 |
| US-11008570-B2 | 3′ end caps for RNAi agents for use in RNA interference | RNGTT, NSUN2, NSUN3 | FBP1 2002/4885P2RY2 4503/4885P2RY4 4586/4885 |
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | RNGTT, NSUN2, NSUN3 | FBP1 2039/4885P2RY2 4504/4885P2RY4 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.